# TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response

> **NCT07510191** · PHASE4 · RECRUITING · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 312 (estimated)

## Conditions studied

- Crohn Disease (CD)

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Infliximab Dose Intensification
- **DRUG:** Adalimumab Dose Intensification
- **DRUG:** Standard-Dose infliximab
- **DRUG:** Standard-Dose Adalimumab

## Key facts

- **NCT ID:** NCT07510191
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07510191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07510191, "TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07510191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*